Skip to content

About Us

The Beginning of NeoVentures

NeoVentures was founded in 2002 and has since become the world leader in aptamer development and applications. The company was cofounded by Ms. Ximena Vedoya and Dr. Gregory Penner based on their observation of the need to bridge the gap between aptamer discovery and commercial application.

Gregory grew up in rural western Canada on a tree nursery. He decided to enroll in agriculture at University because he was inspired by Dr. Norman Borlaug obtaining a Nobel Peace Prize for the green revolution in India and Pakistan. He was trained as an undergraduate in plant breeding and genetics. For his Master’s and PhD he built on this by adding molecular biology. He built a career in cereal molecular breeding, first by leading the development of a cereal biotechnology section composed of fifty researchers at Agriculture Canada in Winnipeg, and subsequently as the global leader for wheat genomics with Monsanto. On this journey he got to know Norman Borlaug well and learned that really famines and starvation are caused by global policies more than by a lack of adequate science or application of science.

Gregory grew up in rural western Canada on a tree nursery. He decided to enroll in agriculture at University because he was inspired by Dr. Norman Borlaug obtaining a Nobel Peace Prize for the green revolution in India and Pakistan. He was trained as an undergraduate in plant breeding and genetics. For his Master’s and PhD he built on this by adding molecular biology. He built a career in cereal molecular breeding, first by leading the development of a cereal biotechnology section composed of fifty researchers at Agriculture Canada in Winnipeg, and subsequently as the global leader for wheat genomics with Monsanto. On this journey he got to know Norman Borlaug well and learned that really famines and starvation are caused by global policies more than by a lack of adequate science or application of science.

Ximena grew up in Buenos Aires Argentina, and decided to enroll in molecular biology at the University of Buenos Aires because of a fascination with nature and the beauty of natural structures. Upon graduation, she emrolled in a Business and Management program at Harvard University and worked in regulatory affairs for Latin American South for Monsanto.

Ximena grew up in Buenos Aires Argentina, and decided to enroll in molecular biology at the University of Buenos Aires because of a fascination with nature and the beauty of natural structures. Upon graduation, she emrolled in a Business and Management program at Harvard University and worked in regulatory affairs for Latin American South for Monsanto.

Both Gregory and Ximena wanted the freedom to try to achieve more for the world with their combined skillsets than they would ever be able to achieve remaining at Monsanto so in 2002 they founded NeoVentures Biotechnology Inc. The initial vision was to use their ingenuity and passion to simply build better solutions in agriculture and in health care. The focus was not on aptamers per se, but on product concepts, the idea of creating substantive improvements that would benefit people’s lives.

The entrepreneur experience was very different than working for the government or for a multinational company. Failure to succeed meant failure as a company. Our success in building NeoVentures has been based on identifying failures early and learning how to solve problems. We have developed into a global leader in aptamer development because we have never been afraid of reinventing the science in order to improve our capacity to deliver product concepts. We have been thought leaders in the development of aptamer selection methods, meta-analysis of data and applications of aptamers. Through many changes we have maintained but refined our initial vision. 

Both Gregory and Ximena wanted the freedom to try to achieve more for the world with their combined skillsets than they would ever be able to achieve remaining at Monsanto so in 2002 they founded NeoVentures Biotechnology Inc. The initial vision was to use their ingenuity and passion to simply build better solutions in agriculture and in health care. The focus was not on aptamers per se, but on product concepts, the idea of creating substantive improvements that would benefit people’s lives.

The entrepreneur experience was very different than working for the government or for a multinational company. Failure to succeed meant failure as a company. Our success in building NeoVentures has been based on identifying failures early and learning how to solve problems. We have developed into a global leader in aptamer development because we have never been afraid of reinventing the science in order to improve our capacity to deliver product concepts. We have been thought leaders in the development of aptamer selection methods, meta-analysis of data and applications of aptamers. Through many changes we have maintained but refined our initial vision. 

Our Vision

We are committed to applying innovative approaches to improving health care. We think that health care itself needs to be reinvented. The top – down approach from disease discovery to treatment has been driven by scientists, clinicians, hospitals and pharmaceutical companies resulting in an industry that is only interested in people once they have been diagnosed with a disease. There is more knowledge held about individuals in regard to their consumer preferences than there is about their ongoing health. We are proud to have been trusted by the many partners we have globally who share our commitment to improving health care. Together we are reinventing diagnostics and drug delivery in ways that will provide individuals with the capacity to own their health trajectories dynamically. 

Our decision and initial vision has been shared and encouraged by so many others, we are convinced that aptamers will effect profound changes for individual health. Every week, as our projects grow and problems are overcome we are increasingly excited about the potential to achieve this vision together as a community. 

We are committed to applying innovative approaches to improving health care. We think that health care itself needs to be reinvented. The top – down approach from disease discovery to treatment has been driven by scientists, clinicians, hospitals and pharmaceutical companies resulting in an industry that is only interested in people once they have been diagnosed with a disease. There is more knowledge held about individuals in regard to their consumer preferences than there is about their ongoing health. We are proud to have been trusted by the many partners we have globally who share our commitment to improving health care. Together we are reinventing diagnostics and drug delivery in ways that will provide individuals with the capacity to own their health trajectories dynamically. 

Our decision and initial vision has been shared and encouraged by so many others, we are convinced that aptamers will effect profound changes for individual health. Every week, as our projects grow and problems are overcome we are increasingly excited about the potential to achieve this vision together as a community. 

Our expertise and passion will help you unlock new market opportunities.

Help Us Reinvent Health Care